Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
The money will be donated to the United Nations Children’s Fund (UNICEF)
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Subscribe To Our Newsletter & Stay Updated
